Hot Features
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-25 | Mr. Paul A. KeelCEO & Director | -12,81k | 300,16k | Sale to Issuer | 23,43 | 154,82k | -7,64% |
| 2026-02-25 | Mr. Eric D. HammesSenior VP & CFO | -2,05k | 60,51k | Sale to Issuer | 29,59 | 41,47k | -4,70% |
| 2026-02-25 | Mr. Stefan NilssonPresident of Nobel Biocare | -182,00 | 5,39k | Sale to Issuer | 29,59 | 17,60k | -1,02% |
| 2026-02-25 | Ms. Veronica AcurioSenior VP & President of Orthodontics | -1,41k | 41,78k | Sale to Issuer | 29,59 | 11,75k | -10,73% |
| 2026-02-25 | Mr. Mark E. NanceSenior VP, General Counsel & Secretary | -3,37k | 99,66k | Sale to Issuer | 29,59 | 81,25k | -3,98% |
| 2026-02-25 | Mr. Mischa M. ReisSVP of Strategy & Corporate Development | -2,98k | 88,06k | Sale to Issuer | 29,59 | 35,32k | -7,77% |
| 2026-02-25 | Mr. Faez KaabiVP, CAO & Corporate Controller | -4,96k | 146,88k | Sale to Issuer | 29,59 | 28,27k | -14,94% |
| 2026-02-25 | Mr. Robert BefidiSenior VP & President of Diagnostics | -2,18k | 64,42k | Sale to Issuer | 29,59 | 22,05k | -8,99% |
| 2026-02-25 | Mr. Paul A. KeelCEO & Director | -11,84k | 350,35k | Sale to Issuer | 29,59 | 143,88k | -7,60% |
| 2026-02-10 | Mr. Mischa M. ReisSVP of Strategy & Corporate Development | -9,68k | 123,33k | Derivative Exercise and Sale | 15,97 - 30,00 | 32,38k | - |
| 2025-11-01 | Mr. Paul A. KeelCEO & Director | -54,10k | 1,10M | Sale to Issuer | 20,35 | 133,78k | -28,79% |
| 2025-08-25 | Mr. Robert BefidiSenior VP & President of Diagnostics | -3,45k | 72,95k | Sale to Issuer | 21,12 | 17,67k | -16,35% |
| 2025-08-25 | Mr. Eric D. HammesSenior VP & CFO | -7,65k | 161,65k | Sale to Issuer | 21,12 | 38,27k | -16,67% |
| 2025-08-25 | Mr. Stefan NilssonPresident of Nobel Biocare | -804,00 | 16,98k | Sale to Issuer | 21,12 | 29,50k | -2,65% |
| 2025-08-25 | Ms. Veronica AcurioSenior VP & President of Orthodontics | -5,42k | 114,51k | Sale to Issuer | 21,12 | 24,88k | -17,89% |
| 2025-08-25 | Mr. Mischa M. ReisSVP of Strategy & Corporate Development | -15,00k | 324,00k | Automatic Disposition | 21,60 | 32,38k | -31,66% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.